C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are two diseases that have a ...

Apellis Pharmaceuticals (NASDAQ:APLS) announced on Tuesday that the U.S. FDA approved its injectable medication Empaveli for ...

C3 Bullion, a pioneer in next-generation gold investment solutions, has launched its India operations, bringing its flagship ...

C3.ai, Inc. (AI) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...

Founded in 2009 by Thomas Siebel, C3.ai's core purpose has always been to deliver AI solutions to enterprises. Its value ...

Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...

Hundreds of owners of Citroen cars have yet to contact the company in relation to its "stop driving" warning affecting almost ...

The FDA approved pegcetacoplan (EMPAVELI; Apellis Pharmaceuticals) as the first treatment for patients aged 12 and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary ...